Matinas BioPharma Holdings, Inc.
(NYSE Amex Equities : MTNB)

( )
MTNB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.26%87.921.3%$848.13m
BIIBBiogen Inc.
1.02%222.501.3%$586.68m
AMGNAmgen Inc.
-0.06%186.591.2%$533.06m
ONCESpark Therapeutics, Inc.
0.47%113.5311.2%$497.94m
GILDGilead Sciences, Inc.
0.03%63.790.9%$468.70m
REGNRegeneron Pharmaceuticals, Inc.
0.82%395.002.6%$283.62m
ILMNIllumina, Inc.
-1.65%303.713.5%$275.40m
VRTXVertex Pharmaceuticals Incorporated
1.28%183.851.9%$247.78m
SRPTSarepta Therapeutics, Inc.
-2.73%118.9215.4%$216.64m
BPTHBio-Path Holdings, Inc.
-12.42%19.25190.1%$203.41m
ALXNAlexion Pharmaceuticals, Inc.
1.60%132.292.0%$187.73m
EXASExact Sciences Corporation
0.07%89.0625.3%$173.12m
AAgilent Technologies, Inc.
0.66%79.511.6%$122.76m
IONSIonis Pharmaceuticals, Inc.
0.18%79.048.3%$109.28m
INCYIncyte Corporation
0.80%86.022.5%$93.70m

Company Profile

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its lead anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.